Literature DB >> 3044441

Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia.

F Frassoni1, M Sessarego, A Bacigalupo, P Strada, M Repetto, S Miceli, D Occhini, R Defferrari, A Marmont.   

Abstract

The cytogenetic and clinical course of three patients allografted for Ph positive chronic myeloid leukaemia are reported. All patients had a peculiar pattern of relapse. Two out of three patients had donor marrow graft pretreated with monoclonal antibody for graft versus host prevention. The cytogenetic relapse was invariably associated with major morphological changes in the marrow indicating that these were also haematological relapses. However, no changes in the peripheral blood count were observed. When relapse occurred in these patients, Ph positive marrow metaphases and host red blood cells ranged from 75% to 100% of the total cell population: thereafter they spontaneously reverted to complete chimaerism. Therefore the presence of leukaemic cells even in considerable amount was not sufficient, per se, to prevail over normal marrow. In addition these observations indicate that relapse was not associated with elimination of the graft: while haemopoiesis was entirely of recipient origin the donor normal stem cells were present and vital although functionally silent. These data suggest that, although TBI remains the more effective tool for eradicating the majority of leukaemic cells, haemopoietic competition between host and donor marrow may have a major impact on leukaemic relapse.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044441     DOI: 10.1111/j.1365-2141.1988.tb02401.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation.

Authors:  Peter Ernst; Andrea Bacigalupo; Olle Ringdén; Tapani Ruutu; Hans J Kolb; Susan Lawrinson; Tomas Skacel
Journal:  Arch Drug Inf       Date:  2008-12

3.  Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation.

Authors:  F Frassoni
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

4.  Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.

Authors:  L M Faber; J van der Hoeven; E Goulmy; A L Hooftman-den Otter; S A van Luxemburg-Heijs; R Willemze; J H Falkenburg
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

5.  Detection of residual host cells in sex-mismatched bone marrow transplantation in various hematological diseases by fluorescence in situ hybridization.

Authors:  M Arif; K Tanaka; T S Kumaravel; M Eguchi; K Iwato; H Dohy; N Kamada
Journal:  Jpn J Cancer Res       Date:  1997-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.